• BVI received four awards in the 2025 Medical Device Network Excellence Awards—for Innovation, Product Launches, R&D, and Investments—recognizing its leadership in advancing ophthalmic technology and global growth.
• Key achievements include the launch of SERENITY IOLs with ISOFOCAL technology, FDA clearance of the Leos™ glaucoma system, and a $1 billion capital raise supporting strategic expansion and continued innovation.

WALTHAM, Mass., July 9th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, has been recognized with four prestigious accolades in the 2025 Medical Device Network Excellence Awards. The company earned top honors in Innovation, Research and Development, Investments, and Product Launches, underscoring its leadership in advancing eye care technology, strategic growth, and breakthrough product development. Leggi altro

• Positions company for several new product launches and scaling of operations to meet rising demand globally
• $1 billion of new capital raised to refinance debt and fund accelerated growth

Waltham, MA, March 10, 2025 – BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the completion of a $1 billion strategic capital raise in partnership with TPG, a leading global alternative asset management firm. This investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, strengthens the company’s financial position as it looks to accelerate product innovation and expand its global footprint. Leggi altro

• Le IOL non diffrattive SERENITY e SERENITY Toric sono la seconda generazione della IOL Premium Monofocale originale e innovativa ISOPURE di BVI, lanciata nel 2019. 

• Queste IOL incorporano la tecnologia ottica brevettata ISOFOCAL per fornire sia visione da lontano che visione intermedia.¹ La piattaforma rivoluzionaria POD a doppio c-loop è progettata specificamente per fornire una correzione precisa dell'astigmatismo e un posizionamento stabile della IOL.² 

• Queste lenti sono progettate per soddisfare la crescente domanda di IOL ottimizzate per visione intermedia, per le quali si prevede un CAGR del 15%.³ 

Waltham, MA, 3 settembre 2024 – BVI ha presentato oggi le sue ultime innovazioni: le IOL Premium Monofocali SERENITY e SERENITY Toric. Queste IOL non diffrattive e asferiche sono la seconda generazione della pionieristica famiglia ISOPURE di BVI, introdotta per la prima volta nel 2019. Utilizzando la tecnologia ottica brevettata ISOFOCAL per bilanciare elegantemente la profondità di fuoco (DoF) e la qualità dell'immagine, queste lenti forniscono una visione da lontano pari a una monofocale ma con una buona visione intermedia fino a 66 cm.¹  Leggi altro

Second BVI Market Debut in Less Than Twelve Months Leggi altro

WALTHAM, Mass. — July 18^th, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium.  This results in a sizeable increase in BVI’s intraocular lens (IOL) business capacity, unlocking new growth opportunities and reinforcing the company’s environmental, social, and governance (ESG) leadership. Leggi altro